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Abstract: Hyaluronic acid (HA) has been utilized for a variety of regenerative medical procedures
due to its widespread presence in connective tissue and perceived biocompatibility. The aim of the
present study was to investigate HA in combination with recombinant human bone morphogenetic
protein 9 (rhBMP9), one of the most osteogenic growth factors of the BMP family. HA was first
combined with rhBMP9 and assessed for the adsorption and release of rhBMP9 over 10 days by
ELISA. Thereafter, ST2 pre-osteoblasts were investigated by comparing (1) control tissue culture
plastic, (2) HA alone, and (3) HA with rhBMP9 (100 ng/mL). Cellular proliferation was investigated
by a MTS assay at one, three and five days and osteoblast differentiation was investigated by alkaline
phosphatase (ALP) activity at seven days, alizarin red staining at 14 days and real-time PCR for
osteoblast differentiation markers. The results demonstrated that rhBMP9 adsorbed within HA
scaffolds and was released over a 10-day period in a controlled manner. While HA and rhBMP9 had
little effect on cell proliferation, a marked and pronounced effect was observed for cell differentiation.
rhBMP9 significantly induced ALP activity, mRNA levels of collagen1α2, and ALP and osteocalcin
(OCN) at three or 14 days. HA also demonstrated some ability to induce osteoblast differentiation by
increasing mRNA levels of OCN and increasing alizarin red staining at 14 days. In conclusion, the
results from the present study demonstrate that (1) HA may serve as a potential carrier for various
growth factors, and (2) rhBMP9 is a potent and promising inducer of osteoblast differentiation. Future
animal studies are now necessary to investigate this combination approach in vivo.
Keywords: osteoinduction; osteoinductive; guided bone regeneration; bone formation; bone
induction; BMP; growth factor; dimensional changes; regenerative therapy; hard tissue regeneration
1. Introduction
Bone morphogenetic proteins (BMPs) have played a pivotal role in modern medicine by directly
influencing the commitment and differentiation of osteoprogenitor cells towards osteoblasts [1].
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When combined with various tissue engineering strategies, they guide the induction of mesenchymal
progenitor cells to differentiate towards bone-forming osteoblasts. As it relates to clinical practice,
recombinant human (rh)BMP2 has been the most widely utilized BMP having been used for a variety
of clinical procedures including spinal fusion, open tibial fractures and various bone augmentation
procedures in regenerative dentistry [2–4]. Despite this, it remains surprising that of all the 15 BMPs,
BMP2 is not necessarily the most osteoinductive of the BMP family [5].
Over a decade ago, two pioneering studies investigated and directly compared the regenerative
potential of 14 BMPs via adenovirus transfection experiments (gene therapy) [5,6]. Cheng et al.
demonstrated that alkaline phosphatase activity (a marker for osteoblast differentiation) was highest
in BMP9 whereas Kang et al. reported that both BMP-6 and -9 had greater in vivo potential for ectopic
bone formation [5,6]. Since those studies utilized adenovirus transfection experiments (an area of
research still not approved by the food and drug administration (FDA) [7], translating these results
into a clinical setting has not been attempted.
BMP9 (also known as growth differentiation factor 2; GDF2) was first identified in 1995 in the
developing mouse liver cDNA libraries [8]. Since then, BMP9 has been shown to play a role in many
pathways including osteogenesis, angiogenesis and chondrogenesis [9–11]. One of the drawbacks
of these few studies characterizing BMP9 were that they were only performed utilizing adenovirus
transfections (gene therapy) with no information regarding its recombinant protein activity [5,6,10,11].
Recently our research group investigated for the first time the regenerative potential of a clinically
viable recombinant source of human (rh)BMP9 [12,13]. In two separate studies, it was found that
rhBMP9 demonstrated up to 10 times more osteopromotion in in vitro osteoblast differentiation when
compared to rhBMP2 [12,13].
Critical to the success of tissue engineering strategies utilizing growth factors are their biomaterial
carrier systems [14]. While the adsorption of BMPs to bone biomaterials has been a highly
studied topic in recent years [15–18], additional strategies designed to facilitate the delivery of
growth factors remain necessary. Hyaluronic acid (HA) has been utilized in recent years in
various medical fields due to its natural constitution in human connective tissues. It is an anionic,
non-sulfated glycosaminoglycan considered an optimal biomaterial for tissue engineering, with
inherent biocompatible and bioresorbable properties [16]. It also plays a prominent role as a
treatment agent for various medical conditions including chronic osteoarthritis, aesthetic surgery,
dermatology, ophthalmology, oral maxilla-facial surgery, as well as for various tissue engineering
applications [17–20]. HA is also available in cross-linked forms for various tissue engineering
applications serving as a scaffold to further improve the overall mechanical properties of the scaffolding
system [21–24].
Therefore, in light of the previous utilization of HA in its cross-linked format as a tissue
engineering scaffold, the aim of the present study was to determine whether HA could also serve
as a carrier for regenerative growth factors such as rhBMP9, one of the most osteogenic growth
factors known to date. First, the growth factor release of rhBMP9 over time was investigated from a
zero- to 10-day period within HA scaffolds. Thereafter, pre-osteoblasts were quantified for their ability
to attach, proliferate and differentiate on HA scaffolds with/without rhBMP9.
2. Methods
2.1. Hyaluronic Acid and Recombinant Human BMP9
Recombinant human (rh)BMP9 was purchased from R&D systems Inc (Minneapolis, MM,
USA). Hyaluronic acid (HA) was kindly provided by Regedent (Zürich, Switzerland) utilizing a
carrier system including cross-linked HA (16 mg HA/mL—cross-linked at 1MDa; Hyadent BG,
BioScience GmbH, Ransbach-Baumbach, Germany, crosslinked to butanediol diglycidyl ether (BDDE)).
Figure 1 demonstrates a scanning electron microscopy (SEM) image used to characterize surface
shape and topography as previously described [25]. For all in vitro experiments, the following three
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groups were utilized: (1) control standard tissue culture plastic (TCP), (2) control HA alone and (3)
HA with 100 ng/mL of rhBMP9. Undifferentiated mouse cell-line ST2 was obtained from RIKEN
Cell Bank (Tsukuba, Japan) and therefore no ethical approval was necessary for the present study.
Cells were cultured in a humidified atmosphere at 37 ◦C in growth medium consisting of DMEM
(Invitrogen Corporation, Carlsbad, CA, USA), 10% fetal Bovine serum (FBS; Invitrogen), and antibiotics
(Invitrogen). For in vitro experiments, cells were seeded onto the various treatment modalities at a
density of 10,000 cells in 24 well culture plates (Corning, New York, NY, USA) for cell proliferation
experiments and 50,000 cells per well in 24-well plates for real-time PCR, ALP assay and alizarin red
experiments. For experiments lasting longer than five days, medium was replaced twice weekly.
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Figure 1. Scanning electron microscopy (SEM) of hyaluronic acid scaffolds at (A) low and (B) high 
magnification. Notice  the  roughened surface  topography of  the cross‐linked HA apparent at very 
high magnification (C). 
Figure 1. Scanning electron microscopy (SEM) of hyaluronic acid scaffolds at (A) low and (B) high
magnification. Notice the roughened surface topography of the cross-linked HA apparent at very high
magnification (C).
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2.2. ELISA Protein Release of rhBMP9 from HA
To determine the quantity of rhBMP9 to be released over time from HA, ELISA quantification
assay was utilized. Since HA is delivered in a liquid/gel system and rapidly densifies and forms a
cross-linking network within a few minutes, HA was delivered simultaneously with rhBMP9, mixed
and allowed to densify for 5 min prior to future investigation. Briefly, after the coating the bottom
of 24-well cell culture dishes with 100 ng/mL of rhBMP9 and HA, dishes were placed at 37 ◦C in a
shaking incubator (E&K Scientific Products, Santa Clara, CA, USA). Over time, the remaining PBS
solution containing unattached rhBMP9 protein was collected, replaced and quantified by a sandwich
ELISA (DY3209, range = 15.60–1000 pg/mL, R&D Systems) for the remaining amount of rhBMP9
protein released from HA according to manufacturer’s protocol. Subtraction of total coated protein
from the amount of un-adsorbed protein was used to determine the amount of growth factor remaining
with HA as previously described [26]. In order to determine the quantity of rhBMP9 protein being
released from HA over time, HA was soaked in 1 ml of PBS at all time points and samples were
collected at various time points including 15, 60 min, 8 h, one, three and 10 days. All samples were
quantified in duplicate and three independent experiments were performed.
2.3. Proliferation Assay
ST2 cells were seeded in 24-well plates at a density of 10,000 cells per well either (1) control
standard tissue culture plastic (TCP), (2) control HA alone and (3) HA with 100 ng/mL of rhBMP9.
Cells were quantified using a MTS assay (Promega, Madison, WI, USA) at one, three and five days for
cell proliferation as previously described [27]. At desired time points, cells were washed with PBS and
quantified using an ELx808 Absorbance Reader (BIO-TEK, Winooski, VT, USA). Experiments were
performed in triplicate with three independent experiments for each condition.
2.4. ALP Activity Assay
At seven days, alkaline phosphatase activity was investigated using Leukocyte alkaline
phosphatase kit (procedure No. 86, Sigma, St. Louis, MO, USA). ST2 cells were fixed by immersing
in a citrate-acetone-formaldehyde fixative solution for 5 min and rinsed in deionized water for 1 min.
Alkaline dye mixture are prepared by 1 mL Sodium Nitrite Solution and 1 mL fast red violet alkaline
solution dissolved in 45 mL of distilled water and 1 mL of Naphtol AS-Bl alkaline solution. Surfaces
were then placed in alkaline dye mixture solution for 15 min protected from light. Following 2 min of
rinsing in deionized water. All images were captured on a Wild Heerbrugg M400 ZOOM Makroskop
(Wild Heerbrugg, Heerbrugg, Switzerland) at the same magnification at the same light intensity and
imported onto Image J software (NIH, Bethesda, MD, USA). Thresholding was used to generate percent
stained values for each field of view.
2.5. Real-Time PCR for Osteoblast Differentiation Markers
Real-time RT-PCR was used to investigate the expression of genes encoding osteoblast
differentiation markers. Total RNA was isolated using High Pure RNA Isolation Kit (Roche, Basel,
Switzerland) at three and 14 days. Primer and probe sequences for genes encoding collagen1α2
(COL1a2), alkaline phosphatase (ALP), osteocalcin (OCN), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were fabricated with Primer sequences according to Table 1. Reverse
transcription was performed with Transcriptor First Strand cDNA Synthesis Kit (Roche). Real-time
RT-PCR was performed using Roche FastStart Universal SYBR Green Master and quantified on
an Applied Biosystems 7500 Real-Time PCR Machine (Biosystems, Life Technologies Corporation,
Carlsbad, CA, USA). A Nanodrop 2000c (Thermo, Wilmington, DE, USA) was used to quantify
total RNA levels. All samples were assayed in duplicate with three independent experiments were
performed. The ∆∆Ct method was used to calculate gene expression levels normalized to total RNA
values and calibrated to control samples.
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Table 1. PCR primers for genes encoding Runx2, ALP, COL1a2, BSP, OCN and GAPDH.
Gene Primer Sequence
mCOL1a2 F GAGCTGGTGTAATGGGTCCT
mCOL1a2 R GAGACCCAGGAAGACCTCTG
mALP F GGACAGGACACACACACACA
mALP R CAAACAGGAGAGCCACTTCA
mOCN F CAGACACCATGAGGACCATC
mOCN R GGACTGAGGCTCTGTGAGGT
mGAPDH F AGGTCGGTGTGAACGGATTTG
mGAPDH R TGTAGACCATGTAGTTGAGGTCA
2.6. Alizarin Red Staining
Alizarin red staining was performed to determine the presence of extracellular matrix
mineralization. After 14 days, cells were fixed in 96% ethanol for 15 minutes and stained with
0.2% alizarin red (Alizarin red S; Sigma) solution in water (pH 6.4) at room temperature for 1 h as
previously described [13]. Alizarin red quantification was performed using images captured on a
Nikon D610 camera with a Heerbrugg M400 ZOOM microscope (Wild Heerbrugg). Image J software
was used to quantify data with the same threshold values for all analyzed.
2.7. Statistical Analysis
All experiments were performed in triplicate with three independent experiments for each
condition. Mean and standard error (SE) were analyzed for statistical significance using one-way
analysis of variance with Tukey posy hoc test (*, p-values < 0.05 was considered significant) for ALP and
alizarin red experiments, and two-way analysis of variance with Tukey post hoc test (*, p-values < 0.05
was considered significant) for proliferation assay and real-time PCR experiments, by GraphPad Prism
6.0 software (GraphPad Software, Inc., La Jolla, CA, USA).
3. Results
3.1. Surface Characteristics of HA Scaffolds and Ability to Hold and Release rhBMP9 over Time
In a first set of experiments, the morphological three-dimensional features of HA scaffolds
were investigated via SEM (Figure 1). It was first found at low magnification that HA displayed a
somewhat wavy surface architecture with many pits and grooves found on its surface (Figure 1A).
Higher magnification imaging revealed the cross-linked pattern of the HA scaffolds (Figure 1B,C).
Thereafter, rhBMP9 was incorporated into the HA and the quantity of total BMP9 released over a
10-day period was observed (Figure 2). It was first found that at early time points, HA maintained a
70% concentration of BMP9 within its scaffold when compared to original loading (Figure 2). rhBMP9
was then released from 70% to 40% within the first 24 h, and thereafter was slowly released up to a
10-day period (Figure 2). At 10 days, HA contained roughly 35% of the initial content of rhBMP9,
demonstrating its ability to hold and slowly release this growth factor over time in a controlled manner
(Figure 2).
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Figure 2. rhBMP9 incorporation into HA scaffolds and its release over time at 0, 15, 60 min; 8, 24 h;
3 and 10 days as quantified by ELISA. An initial burst of released HA was observed between 0 and 1 h.
Thereafter, HA was able to efficiently hold rhBMP9 within its scaffold which was thereafter slowly
released into the surrounding media over a 10-day period.
3.2. Effect of HA Alone and in Combination with rhBMP9 on ST2 Cell Proliferation
Both the regenerative potentials of HA and rhBMP9 were then investigated for the ability for
progenitor osteoblasts to proliferate (Figure 3). While it was found that all cells grew on TCP, HA and
HA scaffolds with rhBMP9, significantly higher cell numbers were observed on control TCP (Figure 3).
Therefore, cells seeded directly to TCP attached and proliferated the fastest when compared to HA or
HA + rhBMP9 (Figure 3). The incorporation of rhBMP9 into HA scaffolds did not significantly influence
cell proliferation at one, three or five days post-seeding when compared to HA alone (Figure 3).
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Figure 3. Proliferation assay at one, three and five days post-seeding of ST2 cells seeded on (1) control
tissue culture plastic (TCP), (2) control HA and (3) HA in combination with 100 ng/mL of rhBMP9.
The highest cell numbers were found on control TCP with no differences observed between HA
with/without rhBMP9 (** denotes significantly higher than all other treatment modalities, p < 0.05).
3.3.Effect of HA on ST2 Cell Differentiation When Combined with rhBMP9
Thereafter, the effects of HA with/without rhBMP9 were tested on osteoblast differentiation
(Figures 4–6). It was first found that while HA had no influence on ALP activity at seven days
post-seeding, its combination with rhBMP9 markedly increased ALP activity (Figure 4). Thereafter,
real-time PCR was utilized to investigate genes encoding COL1a2, ALP and OCN (Figure 5). It was
first found that COL1a2 levels were significantly higher in groups containing both HA and rhBMP9
(three-fold increase) when compared to either control TCP or control HA (Figure 5A). No difference
was observed between TCP or HA and no significant differences were observed between all groups at
14 days (Figure 5A). Similarly, ALP was increased approximately four-fold when compared to control
TCP and control HA groups at three days, yet no differences between groups were observed at 14 days
(Figure 5B). Lastly, OCN expression (a late marker for osteoblast differentiation) demonstrated no
changes in gene expression after three days; however, at 14 days HA alone induced a two-fold
significant increase and HA + rhBMP9 induced a four-fold increase that was significantly higher
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than that of all other groups (Figure 5). Lastly, alizarin red staining was utilized to determine the
mineralization potential of HA and rhBMP9 (Figure 6). It was found that HA alone had the ability
to induce osteoblast differentiation whereas its combination with rhBMP9 further induced over a
four-fold increase in alizarin red staining (Figure 6).
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Figure 5. Real-time PCR of ST2 cells seeded on (1) control tissue culture plastic, (2) control HA and
(3) HA in combination with 100 ng/mL of rhBMP9 for genes encoding (A) collagen 1α2 (COL1a2),
(B) alkaline phosphatase (ALP) and (C) osteocalcin (OCN) at three and 14 days post-seeding (# denotes
significantly lower than all other modalities, p < 0.05; ** denotes significantly higher than all other
treatment modalities, p < 0.05).
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comparison to control TCP and HA alone groups. (B) Quantified data of alizarin red staining from 
color thresholding software (* denotes significant difference, p < 0.05; ** denotes significantly higher 
than all other treatment modalities, p < 0.05). 
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environment should they receive the appropriate cues to fully differentiate into mature bone‐forming 
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from  the  literature have often commented on  the  shortcomings of autogenous bone grafts which 
include limited supply, donor‐site morbidity, additional surgical time and costs [36]. Thus, the aim 
of tissue regeneration is therefore to create a biocompatible artificial replacement material, such as 
metals, xenografts, allografts or synthetic alloplasts, to replace the need to harvest a limited supply 
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More recent research has shown that a variety of hydrogels and nanogels are able to serve as 
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Figure 6. (A) Visual representation of alizarin red stained of (1) negative control HA without cells,
(2) control tissue culture plastic (TCP), (3) co trol HA and (4) HA in combi ation with 100 ng/mL of
rhBMP9 at 14 days post-seeding. Note the intensity of red staini g n HA scaffolds with BMP9 in
comparison to control TCP and HA alone group . (B) Quantified data of alizarin red staining from
lor thresholding s ftware (* enotes significant difference, p < 0.05; ** denotes significantly higher
than all other treatment modaliti s, p < 0.05).
4. Discussion
During osteogenesis, bone formation occurs in a well-orchestrated process when pluripotent
mesenchymal stem cells differentiate into pre-osteoblasts instead of serving as progenitors for
yocytes, adipocytes or chondrocytes [28]. These pre-osteoblasts (such as the ST2 cells utilized
in this study) are then able to differentiate into osteoblasts based on their extracellular matrix
environment should they receive the appropriate cues to fully differentiate into mature bone-forming
osteoblasts [28–30]. Noteworthy, BMPs in general have played an important role in regulating the
tissue pool of pre-osteoblasts and help to significantly induce their subsequent differentiation towards
producing mature bone [31,32].
A variety of regenerative agents have been brought to market in recent years to fill the
large number of bone defects which are a result of trauma, inflammation, congenital disease or
fracture [31–34]. Among the number of available options, autogenous bone has been considered
the gold standard due to its excellent combination of three characteristic properties of bone grafting
materials including osteoconductivity, osteoinductivity and osteogenecity [25,35]. Despite this, various
reports from the literature have often commented on the shortcomings of autogenous bone grafts
which include limited supply, donor-site morbidity, additional surgical time and costs [36]. Thus, the
aim of tissue regeneration is therefore to create a biocompatible artificial replacement material, such as
metals, xenografts, allografts or synthetic alloplasts, to replace the need to harvest a limited supply of
autogenous sources.
More recent research has shown that a variety of hydrogels and nanogels are able to serve as
ideal scaffolds for tissue regeneration by either carrying live progenitor cells or growth factors within
their matrix [30,37–40]. Furthermore, the properties of various gel-like biomaterials, such as a the
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cross-linked gel carrier system utilized in this study, are able to facilitate new bone formation as
quantified either in vitro or in vivo [21–24]. One of the advantages of HA is that it is naturally found
in many connective tissues and thus serves as a completely inert biocompatible material [21–24].
Therefore, in light of these positive previous studies confirming the ability for HA alone to support
osteogenesis, the aim of the present study was to utilize cross-linked HA as a possible carrier system
for growth factors for bone tissue engineering.
Of the list of possible growth factors, BMPs are the most bone-inducing as at least 15 types
of BMPs have been identified in humans [31,32]. Previous analysis of the osteogenic activity of
14 types of human BMPs utilizing transfection experiments (i.e., BMP-2 to BMP-15) found that BMP-2,
BMP-6, and BMP-9 were the most potent factors promoting osteogenic differentiation both in vitro and
in vivo [5,6,10,11]. Kang et al. first reported that an adenoviral vector that transduced osteoblast
progenitor cells will highly and efficiently continue to produce biologically active BMPs inside
mammalian cells favoring mature osteoblast differentiation [5]. Under these bone-inducing conditions,
cells transfected with adBMP-2 showed a 169-fold increase in the activity of the early osteogenic marker
ALP over reference cells transfected with GDP, while cells transfected with adBMP-9 showed a 273-fold
increase in the activity of ALP [5]. Thus, it was concluded that adBMP-9 mediated greater osteoblast
differentiation when compared to adBMP-2 [5]. Unfortunately, these results have since not been
translated to any viable clinical means as the use of adenovirus transfection experimentation (gene
therapy) is still not approved for routine generative procedures by the FDA. Alternative strategies
therefore remain necessary.
The only FDA-approved strategy utilizing growth factors has been via the use of recombinant
sources, where rhBMP2 has been by far the most heavily investigated growth factor for bone
regeneration [41–44]. Despite its widespread use, a number of drawbacks, including a short biological
half-life, lack of a matrix which allow its controlled and sustained release, and inability of the
recombinant molecule presentation after implantation to mimic normal in vivo protein folding by a
BMP-producing cell, have all been reported [45]. Further reported problems include a multitude of
secondary side effects including retrograde ejaculation, antibody formation, postoperative radiculitis,
postoperative nerve root injury, ectopic bone formation, vertebral osteolysis/edema, dysphagia and
neck swelling, hematoma formation, interbody graft lucency, and wound healing complications [46].
Therefore, there remains great interest to find a growth factor that is equally as or more osteopromotive
than rhBMP2, yet does not necessitate such high supra-physiological doses causing an abundance of
secondary effects.
Recently, our group compared the osteogenic potential of rhBMP9 to rhBMP2 and found
that rhBMP9 markedly and significantly induced higher osteoblast differentiation as assessed by
ALP staining, alizarin red staining and real-time PCR for osteoblast differentiation markers [12,13].
Furthermore, we observed that rhBMP9 even at low concentrations of 10 ng/mL was able to
significantly induce over a two-fold increase in osteoblast differentiation when compared to rhBMP2
at a high concentration of 100 ng/mL, representing higher osteogenic potential even at 10-times-lower
doses [12,13]. Therefore, and based on these positive results, the future aim for our group is to find a
suitable biomaterial carrier system capable of loading and releasing rhBMP9 over extended periods of
time to maximize potential new bone formation in future studies.
HA has been utilized as a biomaterial in many medical applications due to its high
biocompatibility with host tissues and its ability to act as a dermal augmentation filler, an adhesion
barrier or a drug delivery carrier [16,47–49]. Its cross-linked feature has been shown to improve the
overall mechanical properties of the scaffold material, further stimulating osteogenesis both in vitro
and in vivo [21–24]. In the present study, we found that HA was able to efficiently load rhBMP9
into its scaffold matrix which was released over a 10-day period (Figure 2). One of the limitations to
this experiment was the fact that growth factor release was only characterized up to 10 days. Future
research investigating its release prolife over longer periods is necessary. Nevertheless, it was shown
that HA alone was able to upregulate the mineralization potential of osteoblasts and certain mRNA
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levels of osteoblast differentiation markers, confirming its ability to induce osteoblast differentiation
when used alone (Figures 5 and 6). More markedly, when HA was combined with rhBMP9, a significant
increase in all tested differentiation parameters was observed including ALP activity, real-time PCR
for genes encoding COL1a2, ALP and OCN, as well as alizarin red staining. While the results from the
present study were not compared directly to rhBMP2 as in our group’s previous publication utilizing
rhBMP9, similar trends were observed, again confirming the efficiency for rhBMP9 to act as a strong
and potent inducer of osteoblast differentiation. Furthermore, HA seems to act as an ideal biomaterial
and carrier system for bone regeneration as it is viscous in nature but allows for three-dimensional
growth of incoming cells within its scaffold. Therefore, as a next strategy our group plans to investigate
this combination in an animal model, to determine to what extent the regenerative potential of rhBMP9
in combination with cross-linked HA scaffolds serves as an inducer of new bone formation.
5. Conclusions
The findings from the present study demonstrate that HA is a purely biocompatible material
able to induce the differentiation of osteoblasts. Furthermore, it was shown that the cross-linking HA
utilized in this study was able to hold and release rhBMP9 over a 10-day period which significantly
further improved osteoblast differentiation by demonstrating higher levels of ALP activity, alizarin
red staining and mRNA levels of osteoblast differentiation markers. The results from this study show
great promise for cross-linking HA to be potentially utilized not only as a regenerative agent for bone
formation, but also as a carrier system capable of holding growth factors such as rhBMP9 or potentially
a variety of others for the treatment of other various medical conditions. Future animal studies are
necessary to determine the essential role of the carrier system and its importance in tissue regeneration
utilizing growth factors in vivo.
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